Cost-Effectiveness Analysis of 3 Therapeutic Schemes for Parkinson's Disease / 中国药房

ABSTRACT

OBJECTIVE:To evaluate the cost-effectiveness of 3 therapeutic schemes in the treatment of Parkinson's disease (PD). METHODS:A total of 94 PD cases were randomly assigned into 3 groupsGroup A (Benserazide tablets +carbidopa and Levodopa controlled release tablets),Group B (Benserazide tablets+Carbidopa and Levodopa controlled release tablets+Selegiline tablets) and Group C (Benserazide tablets+Carbidopa and Levodopa controlled release tablets+Entacapone tablets). After treatment for 8 weeks,the cost-effectiveness analysis were conducted for all the 3 groups. RESULTS:For Group A,B and C,the costs were 448.78,803.89,1 559.89 yuan,respectively; the total effective rates were 56.67%,83.33% and 85.71%,respectively; the cost-effectiveness ratios were 791.92,964.71,1 819.96,respectively. The incremental cost-effectiveness ratios of Group B and C were 1 332.00 and 3 826.14,respectively as against Group A. CONCLUSION:Group B is preferable for PD among the 3 groups.